SUDA - Faster, safer delivery for ex-blockbusters
![](https://assets.livewiremarkets.com/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBcGtJIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--f687b7e2ff49f669994a1ee57393a7d02a433aa7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJYW5CbkJqb0dSVlE2RTNKbGMybDZaVjkwYjE5bWFXeHNXd2RwQWNocEFjZz0iLCJleHAiOm51bGwsInB1ciI6InZhcmlhdGlvbiJ9fQ==--d4026b52d9aa7a676b3d70dbe31c85d930184392/Stuart_Roberts.jpg)
Pitt Street Research and NDF Research
This week we've initiated coverage on SUDA, a Perth-based a drug delivery company focused on oral spray formulations of existing drugs. Imagine these five things:
First, a small pharmaceutical company with a unique platform for reformulating billion-dollar drugs for oral delivery.
Second, that such delivery is not only safer but also much faster-acting.
Third, that the target markets are large, including patients suffering migraine, anxiety, erectile dysfunction, nausea and malaria.
Fourth, that a reformulated approval potentially involves months (not years) and costs a few (not hundreds of) millions.
Fifth, that the small pharma already has its first licensing deal with a top-20 global pharma, as well as two other recent deals. Well, the small pharma is SUDA.
We value it at 9 cents per share base case and 25 cents per share optimistic case using a probability-weighted DCF approach. Our target price of 17 cents per share sits at around the mid-point of valuation range.
2 topics
1 stock mentioned
![Stuart Roberts](https://assets.livewiremarkets.com/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBcGtJIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--f687b7e2ff49f669994a1ee57393a7d02a433aa7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJYW5CbkJqb0dSVlE2RTNKbGMybDZaVjkwYjE5bWFXeHNXd2RwQWNocEFjZz0iLCJleHAiOm51bGwsInB1ciI6InZhcmlhdGlvbiJ9fQ==--d4026b52d9aa7a676b3d70dbe31c85d930184392/Stuart_Roberts.jpg)
I am an equity research professional who worked in stockbroking from 2001 to 2015. After 15 months doing investor relations I returned to equity research with the founding of NDF Research. With Marc Kennis I founded Pitt Street Research in July 2018.
Expertise
![Stuart Roberts](https://assets.livewiremarkets.com/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBcGtJIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--f687b7e2ff49f669994a1ee57393a7d02a433aa7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJYW5CbkJqb0dSVlE2RTNKbGMybDZaVjkwYjE5bWFXeHNXd2RwQWNocEFjZz0iLCJleHAiOm51bGwsInB1ciI6InZhcmlhdGlvbiJ9fQ==--d4026b52d9aa7a676b3d70dbe31c85d930184392/Stuart_Roberts.jpg)
I am an equity research professional who worked in stockbroking from 2001 to 2015. After 15 months doing investor relations I returned to equity research with the founding of NDF Research. With Marc Kennis I founded Pitt Street Research in July 2018.